section name header

Evidence summaries

Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer

There is insufficient evidence of the superiority of gemcitabine compared to other intravesical immunotherapy or chemotherapy for patients with non-muscle invasive bladder cancer. Level of evidence: "D"

The quality of evidence is downgraded by imprecise results (few patients and outcome events) and by indirectness (patient-important outcomes not reported).

Summary

A Cochrane review [Abstract] 1 included 6 studies with a total of 704 subjects. All trials compared gemcitabine to active controls. One study compared a single post-operative instillation of intravesical gemcitabine with a saline placebo in 341 patients and found no significant difference in the rates of tumour recurrence (28% versus 39%, respectively) or recurrence-free survival (HR 0.95, 95% CI 0.64 to1.39, P = 0.77). The rate of progression to invasive disease was greater with gemcitabine (2.4% versus 0.8%). A further trial compared gemcitabine with intravesical mitomycin C and demonstrated that the rates of recurrence (28% versus 39%) and progression (11% versus 18%) were lower with gemcitabine but did not reach statistical significance. The global incidence of adverse events was significantly less with gemcitabine (38.8% versus 72.2%, P = 0.02).Three trials compared gemcitabine with intravesical BCG but a meta-analysis was not possible due to clinical heterogeneity. In untreated patients at intermediate risk of recurrence (primary Ta-T1 no CIS) one trial showed that gemcitabine and BCG were similar with respective recurrence rates of 25% and 30% (P = 0.92) and overall progression equal (P = 1.0). Dysuria (12.5% versus 45%, P < 0.05) and frequency (10% versus 45%, P < 0.001) were significantly less with gemcitabine. In a second trial of high risk patients the recurrence rate was significantly greater with gemcitabine compared to BCG (53.1% and 28.1%, P = 0.04) and the time to recurrence significantly shorter with gemcitabine (25.5 versus 39.4 months, P = 0.042). Finally in a third trial of high risk patients who had failed previous intravesical BCG therapy, gemcitabine was associated with significantly fewer recurrences (52.5% versus 87.5%, P = 0.002) and a longer time to recurrence (3.9 versus 3.1 months, P = 0.9) compared to BCG. Progression rates were similar in both groups (33% versus 37.5%, P = 0.12) with no significant differences in grade 2 or 3 toxicities.The final trial was a marker lesion study which reported greater response rates when intravesical gemcitabine (2 g) was given as three bi-weekly doses (36%) or six weekly doses (40%) compared to a single dose (9%).

Clinical comments

The available evidence suggest that intravesical gemcitabine may have a role in the management of intermediate risk patients, as an alternate choice to mitomycin C in previously treated patients with recurrent disease and in high risk, BGC-refractory patients with NMIBC. However, until further data are available, these conclusions should be interpreted with caution.

Note

Date of latest search: 7.6.2011

    References

    • Jones G, Cleves A, Wilt TJ et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294. [PubMed]

Primary/Secondary Keywords